Vaccinex Stock Performance
| VCNX Stock | USD 3.69 0.13 3.65% |
The entity has a beta of 0.46, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vaccinex's returns are expected to increase less than the market. However, during the bear market, the loss of holding Vaccinex is expected to be smaller as well. At this point, Vaccinex has a negative expected return of -0.22%. Please make sure to validate Vaccinex's value at risk, as well as the relationship between the rate of daily change and relative strength index , to decide if Vaccinex performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vaccinex has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.41 | Five Day Return 4.83 | Year To Date Return (65.02) | Ten Year Return (99.85) | All Time Return (99.85) |
Last Split Factor 1:14 | Last Split Date 2024-02-20 |
1 | Vaccinex Announces Exercise of Warrants for 6.2 Million in Gross Proceeds | 09/18/2024 |
2 | Vaccinex stock hits 52-week low at 4.17 amid sharp annual decline - Investing.com | 09/25/2024 |
3 | Acquisition by Friedberg Albert of 6711552 shares of Vaccinex at 0.3743 subject to Rule 16b-3 | 09/30/2024 |
4 | Disposition of tradable shares by Jill Sanchez of Vaccinex at 615.3 subject to Rule 16b-3 | 10/11/2024 |
5 | Acquisition by Elizabeth Evans of 1341 shares of Vaccinex at 8.21 subject to Rule 16b-3 | 10/22/2024 |
6 | Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b2 trial of Pepinemab at Clinical Trials on Alzheimers Disease Conference on October 31, 202... | 10/24/2024 |
7 | Vaccinex Reports New Findings for SIGNAL-AD Phase 1b2 Trial of Pepinemab at Clinical Trials on Alzheimers Disease Conference in Madrid, Spain | 10/31/2024 |
8 | Acquisition by Maurice Zauderer of 46153 shares of Vaccinex at 3.25 subject to Rule 16b-3 | 11/14/2024 |
9 | Vaccinex reports Q3 figures | 11/18/2024 |
| Begin Period Cash Flow | 6.4 M |
Vaccinex |
Vaccinex Relative Risk vs. Return Landscape
If you would invest 549.00 in Vaccinex on August 31, 2024 and sell it today you would lose (180.00) from holding Vaccinex or give up 32.79% of portfolio value over 90 days. Vaccinex is currently does not generate positive expected returns and assumes 8.8% risk (volatility on return distribution) over the 90 days horizon. In different words, 78% of stocks are less volatile than Vaccinex, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaccinex Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaccinex's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vaccinex, and traders can use it to determine the average amount a Vaccinex's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0245
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VCNX |
Estimated Market Risk
| 8.8 actual daily | 78 78% of assets are less volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vaccinex is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaccinex by adding Vaccinex to a well-diversified portfolio.
Vaccinex Fundamentals Growth
Vaccinex Stock prices reflect investors' perceptions of the future prospects and financial health of Vaccinex, and Vaccinex fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaccinex Stock performance.
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 | ||||
| Operating Margin | (24.66) % | ||||
| Current Valuation | 8.55 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Price To Book | 7.34 X | ||||
| Price To Sales | 27.74 X | ||||
| Revenue | 570 K | ||||
| Gross Profit | (13.7 M) | ||||
| EBITDA | (19.75 M) | ||||
| Net Income | (20.25 M) | ||||
| Cash And Equivalents | 11.4 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 247 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | (2.59) X | ||||
| Cash Flow From Operations | (17.23 M) | ||||
| Earnings Per Share | 7.42 X | ||||
| Market Capitalization | 9.88 M | ||||
| Total Asset | 3.63 M | ||||
| Retained Earnings | (339.93 M) | ||||
| Working Capital | (2.57 M) | ||||
About Vaccinex Performance
Evaluating Vaccinex's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vaccinex has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaccinex has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.58) | (5.86) | |
| Return On Capital Employed | 10.02 | 10.52 | |
| Return On Assets | (5.58) | (5.86) | |
| Return On Equity | 8.76 | 9.20 |
Things to note about Vaccinex performance evaluation
Checking the ongoing alerts about Vaccinex for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaccinex help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaccinex generated a negative expected return over the last 90 days | |
| Vaccinex has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 570 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (13.7 M). | |
| Vaccinex currently holds about 11.4 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27. | |
| Vaccinex has a poor financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: Vaccinex reports Q3 figures |
- Analyzing Vaccinex's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaccinex's stock is overvalued or undervalued compared to its peers.
- Examining Vaccinex's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaccinex's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaccinex's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaccinex's stock. These opinions can provide insight into Vaccinex's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaccinex Stock Analysis
When running Vaccinex's price analysis, check to measure Vaccinex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaccinex is operating at the current time. Most of Vaccinex's value examination focuses on studying past and present price action to predict the probability of Vaccinex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaccinex's price. Additionally, you may evaluate how the addition of Vaccinex to your portfolios can decrease your overall portfolio volatility.